KR20240046643A - 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료 - Google Patents

경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료 Download PDF

Info

Publication number
KR20240046643A
KR20240046643A KR1020247010795A KR20247010795A KR20240046643A KR 20240046643 A KR20240046643 A KR 20240046643A KR 1020247010795 A KR1020247010795 A KR 1020247010795A KR 20247010795 A KR20247010795 A KR 20247010795A KR 20240046643 A KR20240046643 A KR 20240046643A
Authority
KR
South Korea
Prior art keywords
dpp
patients
treatment
diabetes
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247010795A
Other languages
English (en)
Korean (ko)
Inventor
에파 울리케 그래페-모디
토마스 클라인
미하엘 마르크
한스-위르겐 뵈를레
Original Assignee
베링거 인겔하임 인터내셔날 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41426834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20240046643(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 베링거 인겔하임 인터내셔날 게엠베하 filed Critical 베링거 인겔하임 인터내셔날 게엠베하
Publication of KR20240046643A publication Critical patent/KR20240046643A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
KR1020247010795A 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료 Pending KR20240046643A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US10591908P 2008-10-16 2008-10-16
EP08166829.5 2008-10-16
EP08166829 2008-10-16
US61/105,919 2008-10-16
EP09167304 2009-08-05
EP09167304.6 2009-08-05
KR1020227025908A KR20220110860A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료
PCT/EP2009/063511 WO2010043688A1 (en) 2008-10-16 2009-10-15 Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227025908A Division KR20220110860A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료

Publications (1)

Publication Number Publication Date
KR20240046643A true KR20240046643A (ko) 2024-04-09

Family

ID=41426834

Family Applications (6)

Application Number Title Priority Date Filing Date
KR1020117008561A Ceased KR20110066936A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료
KR1020177012224A Ceased KR20170053742A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료
KR1020247010795A Pending KR20240046643A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료
KR1020187009095A Ceased KR20180035948A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료
KR1020207002692A Active KR102427380B1 (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료
KR1020227025908A Ceased KR20220110860A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020117008561A Ceased KR20110066936A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료
KR1020177012224A Ceased KR20170053742A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020187009095A Ceased KR20180035948A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료
KR1020207002692A Active KR102427380B1 (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료
KR1020227025908A Ceased KR20220110860A (ko) 2008-10-16 2009-10-15 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료

Country Status (20)

Country Link
US (3) US20110275561A1 (enExample)
EP (2) EP2349240A1 (enExample)
JP (6) JP2012505859A (enExample)
KR (6) KR20110066936A (enExample)
CN (3) CN102186466A (enExample)
AR (1) AR073876A1 (enExample)
AU (1) AU2009305419B2 (enExample)
CA (1) CA2738367C (enExample)
CO (1) CO6361917A2 (enExample)
EA (1) EA026810B1 (enExample)
EC (1) ECSP11010971A (enExample)
IL (1) IL211370A0 (enExample)
MA (1) MA32872B1 (enExample)
MX (4) MX2011003774A (enExample)
NZ (2) NZ591996A (enExample)
PE (1) PE20110396A1 (enExample)
TN (1) TN2011000176A1 (enExample)
TW (1) TWI520738B (enExample)
UY (1) UY32177A (enExample)
WO (1) WO2010043688A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
NZ588603A (en) 2008-03-26 2012-03-30 Oramed Ltd Methods and compositions for oral administration of a protein of up to 100000 Daltaons, a first protease inhibitor and a second protease inhibitor wherein said protease inhibitors inhibit trypsin
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
LT2395983T (lt) 2009-02-13 2020-07-10 Boehringer Ingelheim International Gmbh Farmacinė kompozicija, apimanti sglt2 inhibitorių, dpp-iv inhibitorių ir, pasirinktinai, papildomą priešdiabetinį agentą, bei jos panaudojimas
NZ594044A (en) * 2009-02-13 2014-08-29 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
KR101819609B1 (ko) 2010-05-05 2018-01-17 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
AU2011249771A1 (en) * 2010-05-05 2012-11-01 Boehringer Ingelheim International Gmbh Pharmaceutical formulations comprising pioglitazone and linagliptin
KR20230051307A (ko) * 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
EP2637669A4 (en) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Heterocyclic compounds and their use
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
AU2016202261B2 (en) * 2010-11-15 2017-11-30 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
MX366629B (es) * 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6218811B2 (ja) * 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2013174768A1 (en) * 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
WO2014106846A2 (en) 2013-01-03 2014-07-10 Oramed Ltd. Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof
CN110075098A (zh) * 2013-03-15 2019-08-02 勃林格殷格翰国际有限公司 利格列汀在心脏和肾脏保护性抗糖尿病治疗中的用途
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
CN106188058B (zh) * 2015-05-29 2020-11-06 江苏天士力帝益药业有限公司 黄嘌呤衍生物
US20200185063A1 (en) 2016-06-05 2020-06-11 Berg Llc Systems and methods for patient stratification and identification of potential biomarkers
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
WO2018058109A1 (en) * 2016-09-26 2018-03-29 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
US7610153B2 (en) * 2002-02-13 2009-10-27 Virginia Commonwealth University Multi-drug titration and evaluation
KR101150449B1 (ko) * 2002-08-21 2012-06-01 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 8-［3-아미노-피페리딘-1-일］-크산틴, 이의 제조방법 및 이를 포함하는 약제학적 조성물
UY28103A1 (es) * 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
AU2003249492A1 (en) * 2003-07-24 2005-02-14 Eswaran Krishnan Iyer Oral compositions for treatment of diseases
ATE534404T1 (de) * 2003-10-03 2011-12-15 Takeda Pharmaceutical Dipeptidylpeptidase-iv-inhibitoren zur behandlung von diabetes-patienten mit sekundärversagen durch sulfonylharnstoffe
JP2005126430A (ja) * 2003-10-03 2005-05-19 Takeda Chem Ind Ltd 糖尿病治療剤
EP1758905B1 (de) * 2004-02-18 2009-04-29 Boehringer Ingelheim International GmbH 8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als dpp-iv hemmer
US7935723B2 (en) * 2004-06-04 2011-05-03 Novartis Pharma Ag Use of organic compounds
US20070259927A1 (en) * 2004-08-26 2007-11-08 Takeda Pharmaceutical Company Limited Remedy for Diabetes
DE102004044221A1 (de) * 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
AU2006327069A1 (en) * 2005-12-23 2007-06-28 Novartis Ag Condensed heterocyclic compounds useful as DPP-IV inhibitors
EP2057160A1 (en) * 2006-08-08 2009-05-13 Boehringer Ingelheim International GmbH Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
PE20090938A1 (es) * 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
UY31291A1 (es) * 2007-08-16 2009-03-31 Composicion farmacéutica que comprende un derivado de pirazol-0-glucosido
US8338450B2 (en) * 2007-09-21 2012-12-25 Lupin Limited Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
BRPI0920699A2 (pt) * 2008-10-16 2020-09-01 Boehringer Ingelheim International Gmbh uso de um inibidor de dpp-4 no tratamento de diabetes em pacientes com controle insuficiente da glicemia apesar de terapia com um fármaco antidiabético oral ou não-oral
EA034869B1 (ru) * 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин

Also Published As

Publication number Publication date
IL211370A0 (en) 2011-04-28
CA2738367C (en) 2017-04-04
CN109700814A (zh) 2019-05-03
MX2022001797A (es) 2022-03-22
JP2022125360A (ja) 2022-08-26
JP2012505859A (ja) 2012-03-08
KR20170053742A (ko) 2017-05-16
JP2018131450A (ja) 2018-08-23
EA026810B1 (ru) 2017-05-31
EA201100621A1 (ru) 2011-12-30
UY32177A (es) 2010-05-31
KR20200013100A (ko) 2020-02-05
ECSP11010971A (es) 2011-05-31
AR073876A1 (es) 2010-12-09
EP2349240A1 (en) 2011-08-03
JP2016164161A (ja) 2016-09-08
TWI520738B (zh) 2016-02-11
KR20180035948A (ko) 2018-04-06
MA32872B1 (fr) 2011-12-01
JP2025029032A (ja) 2025-03-05
CN102186466A (zh) 2011-09-14
EP3150204A2 (en) 2017-04-05
CN108042543A (zh) 2018-05-18
MX375132B (es) 2025-03-06
MX2011003774A (es) 2011-05-23
US20160058769A1 (en) 2016-03-03
CA2738367A1 (en) 2010-04-22
KR20110066936A (ko) 2011-06-17
JP2014129393A (ja) 2014-07-10
KR102427380B9 (ko) 2025-11-13
EP3150204A3 (en) 2017-06-14
KR102427380B1 (ko) 2022-08-01
US20110275561A1 (en) 2011-11-10
US20170368068A1 (en) 2017-12-28
KR20220110860A (ko) 2022-08-09
TW201021802A (en) 2010-06-16
TN2011000176A1 (en) 2012-12-17
JP6811203B2 (ja) 2021-01-13
MX2020009811A (es) 2020-10-14
CO6361917A2 (es) 2012-01-20
NZ591996A (en) 2013-03-28
WO2010043688A1 (en) 2010-04-22
AU2009305419A1 (en) 2010-04-22
PE20110396A1 (es) 2011-07-17
AU2009305419B2 (en) 2015-08-27
JP6262023B2 (ja) 2018-01-17
NZ605207A (en) 2014-07-25

Similar Documents

Publication Publication Date Title
KR102427380B1 (ko) 경구 또는 비경구 당뇨병 치료제에 의한 요법에도 불구하고 혈당 조절이 불충분한 환자에 있어서의 당뇨병 치료
US20250312456A1 (en) Treatment for diabetes in patients inappropriate for metformin therapy
US10034877B2 (en) Treatment for diabetes in patients inappropriate for metformin therapy
JP2012505859A6 (ja) 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療
US11911388B2 (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
JP7174020B2 (ja) 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療
US20240148737A1 (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
HK1157649A (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240329

Application number text: 1020227025908

Filing date: 20220726

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240426

Comment text: Request for Examination of Application